Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcera
January 4, 2023 6:05 AM ESTRVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose testedAcross all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 doseAt the expected Phase 3 dose, among patients who were positive for a biomarker that was prospectively defined in TUSCANY-2, clinical remission and endoscopic improvement rates were 40% and 56%, respectively. Approximately 60% of patients were identified as positive for this biomarkerAt the expected Phase 3 dose, among patients who had been... More
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcera
January 4, 2023 6:05 AM ESTRVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose testedAcross all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 doseAt the expected Phase 3 dose, among patients who were positive for a biomarker that was prospectively defined in TUSCANY-2, clinical remission and endoscopic improvement rates were 40% and 56%, respectively. Approximately 60% of patients were identified as positive for this biomarkerAt the expected Phase 3 dose, among patients who had been... More
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 8:30 AM ESTSAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products... More
